Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1
Xiangsheng Liu(California NanoSystems Institute), Huan Meng(California NanoSystems Institute)
Cited by 132
Related Papers
Use of ratiometrically designed nanocarrier targeting CDK4/6 and autophagy pathways for effective pancreatic cancer treatment
|Nature Communications|2020|68
Synergistic Chemoimmunotherapy Augmentation via Sequential Nanocomposite Hydrogel‐Mediated Reprogramming of Cancer‐Associated Fibroblasts in Osteosarcoma
|Advanced Materials|2023|65
Development of self-assembled multi-arm polyrotaxanes nanocarriers for systemic plasmid delivery in vivo
|Biomaterials|2018|41
Pulmonary Delivery of Specialized Pro-Resolving Mediators-Based Nanotherapeutics Attenuates Pulmonary Fibrosis in Preclinical Animal Models
|ACS Nano|2023|24
Iteratively Designed Nanocarrier for Cell Cycle Arrest, Immune Boost, and T Cell Access
|Research Square|2024|0